MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
Brigham and Women's Hospital · Harvard University · +10 more institutions
Abstract
PURPOSE: Non-small-cell lung cancers (NSCLCs) harboring mutations in MET exon 14 and its flanking introns may respond to c-Met inhibitors. We sought to describe the clinical, pathologic, and genomic characteristics of patients with cancer with MET exon 14 mutations. PATIENTS AND METHODS: We interrogated next-generation sequencing results from 6,376 cancers to identify those harboring MET exon 14 mutations. Clinical characteristics of MET exon 14 mutated NSCLCs were compared with those of NSCLCs with activating mutations in KRAS and EGFR. Co-occurring genomic mutations and copy number alterations were identified. c-Met immunohistochemistry and real-time polymerase chain reaction to detect exon 14 skipping were…
Citation impact
- FWCI
- 58.09
- Percentile
- 100%
- References
- 46
Authors
13- MMMark M. AwadCorresponding
Brigham and Women's Hospital, Harvard University, Merck KGaA, Darmstadt (Germany), Pfizer (United States), AbbVie (United States), Sysmex (Germany), Mirati Therapeutics (United States), Chugai Pharma (United States), AstraZeneca (Brazil), Boehringer Ingelheim (Philippines), Boehringer Ingelheim (Australia), Clovis Oncology (United Kingdom)
- GRGeoffrey R. Oxnard
Brigham and Women's Hospital, Harvard University, Merck KGaA, Darmstadt (Germany), Pfizer (United States), AbbVie (United States), Sysmex (Germany), Mirati Therapeutics (United States), Chugai Pharma (United States), AstraZeneca (Brazil), Boehringer Ingelheim (Philippines), Boehringer Ingelheim (Australia), Clovis Oncology (United Kingdom)
- DMDavid M. Jackman
Brigham and Women's Hospital, Harvard University, Merck KGaA, Darmstadt (Germany), Pfizer (United States), AbbVie (United States), Sysmex (Germany), Mirati Therapeutics (United States), Chugai Pharma (United States), AstraZeneca (Brazil), Boehringer Ingelheim (Philippines), Boehringer Ingelheim (Australia), Clovis Oncology (United Kingdom)
- DODaniel O. Savukoski
Brigham and Women's Hospital, Harvard University, Merck KGaA, Darmstadt (Germany), Pfizer (United States), AbbVie (United States), Sysmex (Germany), Mirati Therapeutics (United States), Chugai Pharma (United States), AstraZeneca (Brazil), Boehringer Ingelheim (Philippines), Boehringer Ingelheim (Australia), Clovis Oncology (United Kingdom)
- DHDimity Hall
Brigham and Women's Hospital, Harvard University, Merck KGaA, Darmstadt (Germany), Pfizer (United States), AbbVie (United States), Sysmex (Germany), Mirati Therapeutics (United States), Chugai Pharma (United States), AstraZeneca (Brazil), Boehringer Ingelheim (Philippines), Boehringer Ingelheim (Australia), Clovis Oncology (United Kingdom)
Topics & keywords
- Exon
- KRAS
- Lung cancer
- Medicine
- Cancer research
- Mutation
- Immunohistochemistry
- Cancer
- Good health and well-being